DarioHealth, Sanofi US Ink $30 Million DTx Adoption Agreement

Digital management company for chronic conditions DarioHealth has entered into a $30 million strategic partnership with biopharma giant Sanofi to accelerate adoption of Dario’s suite of tools in the US

The agreement with the multinational pharmaceutical company’s US division will focus on “significantly” expanding Dario’s sales to health plans and selecting employers. The deal also allows the companies to develop new or improved tools for Dario’s platform and work on research to support the commercialization of those digital therapies.

“Dario’s proven digital therapeutic solutions and innovative technologies perfectly complement Sanofi’s scientific expertise, market access and scale, and provide a foundation for long-term success in support of Sanofi’s goal to expand into digital health therapies for chronic conditions,” Dario CEO Erez said Raphael in a statement.


The companies position the partnership as a way to accelerate the adoption of digital therapies for the treatment of chronic conditions widespread in the US and driving up most health care expenditures.

Dario’s platform includes tools for managing diabetes, hypertension, weight, musculoskeletal disorders, and behavioral problems.

“Our partnership with Dario is another step toward accelerating Sanofi’s mission to reverse the course of chronic disease by integrating healthcare and technology in a way that empowers people to improve their health,” Gustavo Pesquin, head of US general medicine at Sanofi, said in a statement.

“We are excited to help payers realize the potential digital health can bring to the patient experience, and we look forward to continuing to innovate with Dario on the next generation of therapies for chronic conditions.”


This is not the first collaboration between digital health and pharma. Earlier this year, Swedish startup Alex Therapeutics announced a strategic commercial agreement with Pfizer aimed at creating digital therapies for nicotine addiction, initially in Germany.

Consumer genetics company 23andMe recently extended their drug discovery partnership with GlaxoSmithKline, a deal that began in 2018. Although the partnership was dissolved in 2019, Pear Therapeutics had a commercialization partnership with Novartis for its reSET and reSET-O prescription digital therapies.

In 2019, Sanofic entered into a deal with Happify Health aimed at treating anxiety and depression in patients with multiple sclerosis. It also recently signed a deal with Exscientia aimed at discovering AI-based medicines.

Dario, meanwhile, has expanded the clinical scope of his platform. In January 2021 it repurchased the digital MSK space the acquisition of Upright Technologies and launched its tool, Dario Move, in October. It also picked up digital mental health company wayForward in May.